In previous studies we showed that nitric oxide (NO) donors and synthetic doxorubicins (DOXs) modified with moieties containing NO-releasing groups -such as nitrooxy-DOX (NitDOX) or 3phenylsulfonylfuroxan-DOX (FurDOX) -overcome drug resistance by decreasing the activity of ATP-binding cassette (ABC) transporters that can extrude the drug. Here we have investigated the biochemical mechanisms by which NitDOX and FurDOX exert antitumor effects.
Introduction
Doxorubicin (DOX), also known as adriamycin, is an antibiotic belonging to the class of anthracyclines, widely used to treat solid and hematological malignancies. The molecular mechanisms that underlie the DOX anticancer effects include DNA damage, inhibition of topoisomerase II, induction of oxidative stress (synthesis of reactive oxygen species, ROS, and reactive nitrogen species, RNS), altered metabolism of Ca ++ ions, and activation of host immune system against the tumor 1 .
The limitations to DOX efficacy in cancer therapy are of two types: cardiotoxicity, which can occur as both acute and chronic dose-related forms, and development of resistance through different mechanisms, the main of which is the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (Pgp/ABCB1), multidrug resistance-associated proteins (MRPs/ABCCs) and breast cancer resistance protein (BCRP/ABCG2), which actively extrude the drug from tumor cells by enhanced chemiluminescence (Immun-Star, Bio-Rad). 10 μg proteins from nuclear extracts or mitochondrial extracts (see below) were probed with the same antibodies, using respectively an anti-TATA Box Binding Protein (Santa Cruz Biotechnology) or an anti-VDAC/porin (Abcam) antibody, to check the equal control loading.
To analyze the presence of nitrated proteins, the whole cell extract was subjected to immunoprecipitation using a rabbit polyclonal anti-nitrotyrosine antibody (Millipore, Bedford, MA). Immunoprecipitated proteins were separated by SDS-PAGE and probed with anti-Pgp/ABCB1, anti-MRP1/ABCC1, anti-MRP2/ABCC2 or anti-BCRP/ABCG2 antibodies, as previously described.
Extracellular lactate dehydrogenase (LDH) activity
To verify the cytotoxic effect of DOX, the extracellular medium was centrifuged at 12,000 × g for 15 min to pellet cellular debris, whereas cells were washed with fresh medium, detached with trypsin/EDTA, re-suspended in 0.2 ml of 82.3 mmol/L triethanolamine phosphate-HCl (pH 7.6) and sonicated on ice with two 10 s bursts. LDH activity was measured in the extracellular medium and in the cell lysate, as reported 20 . The reaction was followed for 6 min, measuring absorbance at 340 nm with Packard EL340 microplate reader (Bio-Tek Instruments, Winooski, VT) and was linear throughout the time of measurement. Both intracellular and extracellular enzyme activity was expressed in μmol NADH oxidized/min/dish, then extracellular LDH activity was calculated as percentage of the total LDH activity in the dish.
Nitrite production
Confluent monolayers in 35 mm-diameter Petri dishes were incubated in fresh medium under the experimental conditions indicated in Results. Nitrite production was measured by adding 0.15 mL of cell culture medium to 0.15 mL of Griess reagent in a 96-well plate, and after a 10 min incubation at 37°C in the dark, the absorbance was detected at 540 nm with a Packard EL340 microplate reader (Bio-Tek Instruments). A blank was prepared for each experiment in the absence of cells, and its absorbance was subtracted from the one obtained in the presence of cells. Nitrite concentration was expressed as nmol/mg cell proteins.
Intracellular doxorubicin accumulation
The amount of DOX of whole cells lysates, nuclear and mitochondrial extracts was measured fluorimetrically as described 5 , using a PerkinElmer LS-5 spectrofluorimeter (PerkinElmer, Waltham, MA). Excitation and emission wavelengths were 475 and 553 nm, respectively. A blank was prepared in the absence of cells in each set of experiments and its fluorescence was subtracted from the one measured in each sample. Fluorescence was converted in nmol DOX/mg cell proteins using a calibration curve prepared previously.
Topoisomerase II assay.
The in vitro activity of topoisomerase II was measured using the Topoisomerase II Drug Screening Kit (Topogen Inc, Port Orange, FL), following the manufacturer's instructions. 250 ng of the supercoiled pHOT1 plasmid were incubated with 5 U of purified human Topoisomerase IIa (TOPOGen Inc) at 37°C for 30 min, in the presence of DOX, NitDOX or etoposide. The reaction was stopped with SDS 10% w/v and 1 μg proteinase K was added in each tube. The products were resolved on a 1% w/v agarose gels, stained with 0.01% v/v ethidium bromide. The appearance of a band corresponding to linearized plasmid was taken as an index of active topoisomerase II. As control of the enzyme specificity, supercoiled pHOT1 was incubated in the absence of topoisomerase II and treated as reported above.
Doxorubicin uptake.
Drug uptake was measured as described in 21 , with minor modifications. Cells were washed and pre-incubated for 5 min at 37°C in uptake buffer (125 mmol/L NaCl, 20 mmol/L NaHCO 3 , 3 mmol/L KCl, 1.8 mmol/L CaCl 2 , 1 mmol/L KH 2 PO 4 , 1.2 mmol/L MgSO 4 , 10 mmol/L glucose, 10 mmol/L Hepes, pH 7.4), then incubated for 10 min with DOX or NitDOX, in the absence or presence of tetraethylammonium (TEA) chloride. The assay was stopped by diluting 1:10 the sample in ice-cold uptake buffer. Cells were detached and centrifuged at 13,000 x g for 30 s, washed three times with 1 mL ice-cold uptake buffer, lysed in 1 mL ethanol/0.3 N HCl and sonicated. The DOX amount was measured fluorimetrically as reported above.
Octanol/water partition coefficient determination.
The lipophilicity of DOX and NitDOX was estimated by measuring their partitioning between noctanol and water buffered at pH 7.4. The distribution coefficients (log D 7.4 s) were obtained by shake-flask technique at room temperature. The organic (n-octanol) and aqueous phase (50 mmol/L phosphate buffer, pH=7.4; ionic strength adjusted to 0.15 mol/L with KCl) were mutually saturated by shaking for 4 h. The compounds were solubilised in the buffered aqueous phase at a concentration of about 0.1 mmol/L and an appropriate amount of n-octanol was added. The two phases were shaken for about 30 min, by which time the partitioning equilibrium of solutes is reached, and then centrifuged (10,000 x g 10 min). The concentration of the solutes was measured in the aqueous phase by reverse phase-HPLC. Each log D value is an average of at least six measurement. All the experiments were performed avoiding exposure to light.
Confocal microscope analysis.
5×10 5 cells were grown on sterile glass coverslips and treated as described in the Results section, then rinsed with PBS, fixed with 4% w/v paraformaldehyde for 15 min, washed three times with PBS and incubated with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, diluted 1: 20,000) for 3 min at room temperature in the dark. Fluorescently labelled cells were washed three times with PBS and once with water, then the slides were mounted with 4 μl of Gel Mount Aqueous Mounting and examined. In the experiments concerning NitDOX intracellular localization, cells were previously transfected with expression vectors encoding for the GFP-fused-leader sequence of E1α pyruvate dehydrogenase to label mitochondria, the GFP-fused-KDEL sequence of calreticulin to label endoplasmic reticulum, the GFP-fused N-acetylgalactosaminyltransferase 2 to label Golgi apparatus (Cell Light BacMan 2.0, Invitrogen), then incubated for 6 h with 10 µM NitDOX and prepared for the analysis by confocal microscope as reported above. For each experimental point, a minimum of 5 microscopic fields were examined.
Cytosol-nucleus separation.
The cytosolic and nuclear extracts were prepared as reported previously 20 . After protein quantification, samples were stored at -80°C until use.
Mitochondria isolation and complex I-IV activity.
Mitochondria were extracted as described earlier 22 . A 50 μL aliquot was sonicated and used for the measurement of protein content or Western blotting; the remaining part was stored at -80°C until use. To confirm the presence of mitochondrial proteins in the extracts, 10 μg of each sonicated sample were subjected to SDS-PAGE and probed with an anti-VDAC/porin antibody (data not shown).
The activity of the mitochondrial complexes I-IV was measured on 10 μg of non-sonicated mitochondrial extracts, as reported 23 . Each reaction was followed for 5 min, using a Lambda 3 spectrophotometer (PerkinElmer).
HPLC and LC-ESI-MS analyses of cell fractions.
DOX or NitDOX were incubated for 24 h in HT29 cells at 10 µmol/L to operate at a concentration that granted the optimal sensitivity of HPLC analysis. The reverse-phase (RP) HPLC procedure allowed the separation and quantitation of compounds and degradation products in cytosolic, nuclear, and mitochondrial fractions. Cellular fractions were obtained as described above and diluted with equal volume of acetonitrile in order to deproteinize the sample. The sample was sonicated, vortexed and then centrifuged for 10 min at 2,150 x g, the clear supernatant was filtered by 0.45 m polytetrafluoroethylene filters and analysed by RP-HPLC or LC-ESI-MS methods.
HPLC analyses were performed with a HP 1100 chromatograph system (Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), a membrane degasser (G1379A), a diode-array detector (DAD) (model G1315B) integrated in the HP1100 system. Data analyses were processed using a HP ChemStation system (Agilent Technologies). The analytical column was a HyPurity Elite C18 (250×4.6mm, 5 µm; Hypersil, ThermoQuest Corporation, UK).
The mobile phase consisting of acetonitrile/phosphate buffer (50 mmol/L, pH 2.0) at flow-rate = 1.0 mL/min with gradient conditions: 70% PBS until 5 min, from 70 to 35% PBS between 5 and 15 min, and from 35 to 70% PBS between 15 and 20 min. The injection volume was 100 L (Rheodyne, Cotati, CA). The column effluent was monitored at 234 mn and 480 nm referenced against a 700 nm wavelength. Quantitation of DOX and NitDOX was done using calibration curves of compounds: the linearity of the calibration curves was determined in a concentration range of 1-50µM (r 2 > 0.99); quantitative analysis of their metabolites was also conducted using DOX (for doxorubicinol) and NitDOX (for denitrated derivatives) as references. The amount of glucose transformed into CO 2 through the TCA cycle was calculated as described 24 and expressed as nmol CO 2 /h/mg of cell proteins.
LC-ESI

ATP synthesis.
Quantitative determination of ATP in mitochondria was performed using the ATP Bioluminescent Assay Kit (FL-AA, Sigma Aldrich Co.), following the manufacturer's instruction. The luminescence was recorded using a Magic Lite Analyzer (Ciba Corning Diagnostic Corp., Cambridge, MA). ATP was quantified as arbitrary light units and then converted into nmol ATP/mg mitochondrial proteins, according to a calibration curve previously set.
ROS and RNS measurement.
For ROS measurement, cells were rinsed with PBS and loaded with 10 μmol/L 5-(and-6)chloromethyl-2',7'-dichorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-AM) for 10 min at 37°C, then washed and re-suspended in 0.5 mL PBS. The intracellular fluorescence was detected by flow cytometry, using a FACSCalibur system (Becton Dickinson), with a 530 nm bandpass filter. For each analysis 100,000 events were collected and analyzed by the CellQuest software (Becton Dickinson).
The amount of intracellular nitrotyrosine, considered as an index of RNS generation 25 , was measured by the Nitrotyrosine ELISA kit (Hycult Biotechnolohgy, The Netherlands), following the manufacturer's instructions. The absorbance was read with a Packard EL340 microplate reader (Bio-Tek Instruments) and converted into pmol/mg cell proteins according to the titration curve.
Lipid peroxidation.
Cells were washed with fresh medium, detached and re-suspended in 1 mL of PBS. Lipid peroxidation was detected by measuring the intracellular level of malonyldialdehyde (MDA), an end product of polyunsaturated fatty acids and related esters breakdown, with the Lipid Peroxidation Assay kit (Oxford Biomedical Research, Oxford, MI), which uses the reaction of Nmethyl-2-phenylindole with MDA in the presence of hydrochloric acid to yield a stable chromophore with maximal absorbance at 586 nm. The absorbance was measured with a Packard EL340 microplate reader (Bio-Tek Instruments). Results were expressed as nmol/mg cell proteins, according to a titration curve previously prepared.
Cytochrome c release.
10 μg of proteins from cytosolic and mitochondrial fraction were subjected to Western blotting to assess the cytosolic release of cytochrome c, taken as an index of apoptosis 26 , using an anticytochrome c antibody (Becton Dickinson).
Caspase activity.
Cells were lysed in 0. The reaction was stopped by adding 0.75 mL ice-cold 0.1% w/v trichloroacetic acid and the fluorescence of AMC fragment released by active caspases was read using a LS-5 spectrofluorimeter (PerkinElmer). Excitation and emission wavelengths were 380 nm and 460 nm, respectively. Fluorescence was converted in pmol/μg cell proteins, using a calibration curve prepared previously with standard solutions of AMC.
Statistical Analysis.
All data in text and figures are provided as means + SD. The results were analyzed by a one-way analysis of variance (ANOVA) and Tukey's test. p < 0.05 was considered significant.
Results
Nitrooxy-doxorubicin is more effective than doxorubicin in drug-resistant cancer cells.
To monitor the intracellular drug accumulation and toxicity of DOX, NitDOX and FurDOX, we chose the model of the drug-sensitive human colon cancer HT29 cells and the drug-resistant counterpart HT29-dx cells, which express higher levels of several ABC transporters extruding DOX, such as Pgp/ABCB1, MRP1/ABCC1, MRP2/ABCC2 and BCRP/ABCG2, than HT29 cells ( Figure 1A ). At 5 μmol/L, a concentration of DOX that was cytotoxic in HT29 cells, but not in HT29-dx cells 5 , all the drugs accumulated time-dependently in HT29 cells, with FurDOX > NitDOX > DOX ( Figure 1B ). DOX was not retained in HT29-dx cells, in contrast to NitDOX and FurDOX whose accumulation increased as function of time also in drug-resistant cells. The content of FurDOX was higher than that of NitDOX at each time point ( Figure 1B ). A similar trend was observed for the extracellular nitrite amount ( Figure 1C ), taken as an index of NO released by the compounds (for NitDOX and FurDOX) or synthesized by the cells themselves: DOX induced a significant increase of nitrite only in HT29 cells after 24 h, whereas with NitDOX and FurDOX the NO levels were higher than with DOX, raised earlier and in both sensitive and resistant cells.
FurDOX was a stronger NO releaser than NitDOX ( Figure 1C ). Cell toxicity, measured as the release of LDH in the extracellular medium, was produced by DOX only in HT29 cells and not in HT29-dx cells; on the opposite, the NO-releasing drugs were cytotoxic both in drug-sensitive and drug-resistant cells ( Figure 1D ).
To clarify whether NO was the main responsible of the cytotoxicity of the compounds, in a parallel experimental set we used DOX in association with different NO-donors -i.e. the methyl ester of acid containing nitrooxy moiety (NitE), the methyl ester of acid containing phenylsulfonylfuroxan moiety (FurE), SNP, spermine NONOate (NONO) -, each showing different kinetics and potency of NO release (Supplementary Figure S2A ). All the NO-donors increased the intracellular retention of DOX at 24 h (Supplementary Figure S2B) ; the most potent NO-donors (FurE and NONO) were also the most potent enhancers of the intracellular accumulation of DOX (Supplementary Figure   S2B ). They were also cytotoxic per se in HT29 and HT29-dx cells (Supplementary Figure S2C Figure S2B and Figure 1B) . Unexpectedly, the release of LDH was higher with NitDOX than with DOX + NitE, as well as with FurDOX than with DOX + FurE (compare Supplementary Figure S2C and Figure 1D ), suggesting that NitDOX and FurDOX may have additional mechanisms of toxicity than DOX co-incubated with the corresponding NO-releasing molecule.
NitDOX and FurDOX were significantly more accumulated than DOX also in other human cancer cells possessing an acquired drug-resistant phenotype, such as A549-dx and K562-dx cells (which, as expected, retained less DOX than the sensitive counterparts A549 and K562), and in primary cells of malignant mesothelioma (MM98), which again contained a lower amount of DOX than the non-transformed mesothelial cells Met5A (Supplementary Figure S3A ).
We checked in parallel the release of LDH from H9c2 cardiomyocytes: whereas DOX and NitDOX did not differ for the intracellular accumulation and the toxicity, FurDOX was significantly more accumulated and elicited a stronger cytotoxic effect (Supplementary Figure S3B) .
Similarly, in non transformed human colon epithelial CCD-18Co cells, DOX and NitDOX did not differ in terms of intracellular drug accumulation (Supplementary Figure S4A ), nitrite and cytotoxicity (Supplementary Figure S4B) , whereas FurDOX was the most retained within CCD-18Co cells, the most potent inducer of NO and the most potent inducer of cytotoxicity (Supplementary Figure S4A-B ).
In consequence of the higher toxicity of FurDOX in cardiomyocytes (Supplementary Figure S3B) and non transformed epithelial cells (Supplementary Figure S4B) , we withdrew FurDOX from the subsequent experiments and focused our investigation on NitDOX, which was more effective than DOX in accumulating into all cell lines we analyzed, without exerting a greater toxicity than DOX on cardiomyocytes and non transformed colon cells.
Nitrooxy-doxorubicin does not inhibit topoisomerase II and has a different uptake and intracellular distribution than doxorubicin.
Since one of the anticancer mechanisms of DOX is the inhibition of topoisomerase II, we first investigated whether the addition of the nitrooxy group enhanced this property in an in vitro assay ( Figure 2 ). Purified topoisomerase II was inhibited dose-dependently by DOX, as well as by etoposide, the other inhibitor profiled. NitDOX poorly inhibited topoisomerase II ( Figure 2 ). This result led us to hypothesize that the cell toxicity of NitDOX relies on different mechanisms, such as more favorable kinetics of uptake or cellular targets different from nuclear topoisomerase II.
NitDOX was more rapidly uptaken than DOX ( Figure 3A ). The uptake of DOX was lower in HT29-dx cells (1.94 + 0.19 nmol/mg prot, corresponding to 0.41 + 0.06 µmol/L) than in HT29 cells (3.94 + 0.43 nmol/mg prot, corresponding to 0.91 + 0.03 µmol/L), whereas the entry of NitDOX was the same in drug-sensitive (4.74 + 0.58 nmol/mg prot, corresponding to 1.14 + 0.07 µmol/L) and drug-resistant cells (4.72 + 0.91 nmol/mg prot, corresponding to 1.01 + 0.09 µmol/L). In addition, the uptake of DOX was reduced in the presence of TEA ( Figure 3A) , an inhibitor of the SLC22A4 transporter, a member of the organic cation/zwitterion transporters family that mediates the entry of DOX by facilitated transport 21 . SLC22A4 was slightly higher in HT29 cells than in HT29-dx cells ( Figure 3B ). Since the uptake of NitDOX was equal in both cell lines and did not change in the presence of TEA ( Figure 3A) , it was likely a SLC22A4-independent process. NOendogenously produced or released from the nitrooxy groupwas not responsible for the greater uptake of NitDOX, as suggested by the finding that the uptake of the compound was not reduced by NO scavengers, such as 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) or packed red blood cells. Similarly, NO scavengers did not affect the uptake of DOX (data not shown).
Another remarkable difference between DOX and NitDOX was the intracellular distribution:
whereas DOX accumulated in the nuclei of HT29 cells, NitDOX exhibited a prominent extranuclear localization at 30 min, 1, 3, 6 h (data not shown) and 24 h ( Figure 3C ). The quantitative fluorimetric analysis of DOX and NitDOX in nuclear and cytosolic extracts confirmed what we had previously observed in whole HT29 cells ( Figure 1D ). In HT29-dx cells the amount of DOX was lower in both nuclei and cytosol ( Figure 3D ) and was undetectable by microscope analysis (data not shown).
NitDOX, although a bit less accumulated in HT29-dx cells, maintained the same distribution pattern observed in HT29 cells, reaching the highest concentration in cytosolic fractions ( Figure 3D ). The co-incubation of DOX and NO-donors increased the amount of DOX in nuclear extracts, without significant differences between each compound (Supplementary Figure S5A) . Only a small increase of DOX was detectable in cytosolic extracts (Supplementary Figure S5A) . SLC224A was absent from nuclear extracts (data not shown) and TEA was devoid of effect on the drugs distribution (data not shown). Pgp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 were present in nuclear extracts and were nitrated by DOX in HT29 cells and by NitDOX in HT29 and HT29-dx cells (data not shown); however, PTIO, which prevented the nitration of the transporters, did not change the distribution of DOX or NitDOX (data not shown). These results indicate that the exclusion of NitDOX from nucleus was not due to a different uptake via SLC22A4 protein or to a different efflux from nuclear envelope mediated by ABC transporters. DOX and NitDOX had a different lipohilicity: the octanol/water distribution coefficient at pH 7.4 (log D 7.4 ) was 0.47 + 0.08 for DOX and 2.72 + 0.09 for NitDOX (n =6), suggesting that NitDOX should be more favored to enter cells by a simple diffusion mechanism. The different hydrophobicity may explain also the different intracellular distribution of NitDOX and DOX.
HPLC analysis of nuclear and cytosolic extracts from HT29 cells confirmed that DOX was mainly present in the nucleus and NitDOX outside it (Table 1 ; Supplementary Figure S6 ).
Nitrooxy-doxorubicin is localized to mitochondria and impairs mitochondria metabolism.
To gather more information about the intracellular localization of NitDOX, we transfected HT29 cells with GFP-fused-expression vectors targeting specific organelles: NitDOX was mainly found in mitochondria and endoplasmic reticulum, whereas it was absent from the Golgi apparatus ( Figure   4A ).
Interestingly, NitDOX reached the same concentration in mitochondria of HT29 and HT29-dx cells and was significantly higher than DOX ( Figure 4B ). Conversely, none of NO-donors increased the intramitochondrial accumulation of DOX, with the exception of a small but not significant increase promoted by NitE ( Supplementary Figure S5B ). Mitochondria of HT29 and HT29-dx cells have several ABC pumps transporting DOX, such as Pgp/ABCB1, MRP1/ABCC1, MRP2/ABCC2 and BCRP/ABCG2 ( Figure 4C ). Interestingly, the amount of MRP1/ABCC1 was higher in HT29-dx cells ( Figure 4C ): this element may explain the lower accumulation of DOX in the mitochondrial fraction of this cell population ( Figure 4B ). DOX in HT29 and NitDOX in both HT29 and HT29-dx cells elicited the tyrosine nitration of MRP1/ABCC1 and BCRP/ABCG2, an event that was prevented by the addition of PTIO ( Figure 4C ). SLC22A4 was not detectable nor TEA affected the intra-mitochondrial accumulation of DOX and NitDOX (data not shown).
In HT29-dx cells the oxidative mitochondria metabolism was more active than in HT29 cells, as demonstrated by the higher flux through the TCA cycle ( Figure 5A) , the higher electron flux through complex I ( Figure 5B ) and the higher synthesis of ATP ( Figure 5F ). In keeping with the different intramitochondrial accumulation, DOX reduced TCA flux, complex I activity and ATP synthesis in HT29 cells, but was devoid of effect in HT29-dx cells ( Figure 5A , 5B and 5F), where it was poorly retained into mitochondria ( Figure 4B ). On the contrary, NitDOX, which accumulated in mitochondria of both drug-sensitive and drug-resistant cells ( Figure 4B ), equally decreased in these cells TCA cycle, complex I activity and ATP synthesis ( Figure 5A , 5B and 5F). No changes occurred in the activity of other steps of mitochondrial electron chain, as determined by the electron flux through the segment complex I to III ( Figure 5C ), through the segment complex II to III ( Figure 5D ) and through complex IV ( Figure 5E ). These data suggest that the effects elicited by the anthracyclines on mitochondrial metabolism have rather specific targets. For both DOX in HT29 cells and NitDOX in HT29 and HT29-dx cells, the changes on TCA activity, complex I and ATP synthesis were abrogated by the addition of PTIO ( Figure 5A, 5B and 5F ).
Furthermore, the rate of DOX and NitDOX metabolism within mitochondria was different: in mitochondrial extracts of HT29 cells treated with DOX, we detected both DOX and a more hydrophilic metabolite, suggestive of doxorubicinol 27 (DOX-ol, Table 1 ; Supplementary Figures   S6 and S7 ). On the contrary in mitochondria of NitDOX-treated cells, we found mainly NitDOX, together with DOX obtained from the hydrolysis of the ester group (about 14%), and a considerable percentage (about 25%) of the two denitrated metabolites deriving from NO release (NitDOX denitrate 1 and 2, Supplementary Figures S6 and S7) . Structures of the metabolites generated from DOX and NitDOX are summarized in the Supplementary Figure S8 .
Nitrooxy-doxorubicin exerts a strong oxidative/nitrosative stress and activates the intrinsic pathway of apoptosis in resistant cells.
DOX increased the amount of ROS ( Figure 6A ) and the amount of nitrotyrosine, indicator of RNS generation 25 (Figure 6B ) in HT29 cells, but not in HT29-dx cells. These events however were not sufficient to produce significant oxidative damage, because no marked change in lipid peroxidation was detected ( Figure 6C ). On the contrary, NitDOX effectively raised the amount of ROS and RNS in HT29 well as well as in HT29-dx cells ( Figure 6A and 6B) . Accordingly, only NitDOX produced a strong oxidative damage in both cell lines, as suggested by the significant increase of MDA level ( Figure 6C ). NO was crucial in the genesis of this type of damage, since the effect of NitDOX was reduced by the addition of PTIO ( Figure 6C ).
Finally, to determine whether the impairment of mitochondria metabolism and the increased oxidative damages elicited by NitDOX effectively resulted in cell death, we analyzed the release of cytochrome c into the cytosol and the subsequent activation of the caspases involved in the intrinsic apoptotic pathway. Whereas DOX produced a small cytosolic release of cytochrome c ( Figure 7A ), followed by an increased activity of caspase-9 ( Figure 7B ) and caspase-3 ( Figure 7C ) only in HT29 cells, NitDOX was a stronger inducer of cytochrome c release ( Figure 7A ) and a stronger activator of caspase-9 ( Figure 7B ) and caspase-3 ( Figure 7C ) in both HT29 and HT29-dx cells. Again, the removal of NO by PTIO, prevented all the pro-apoptotic effects of DOX and NitDOX ( Figure 7A-7C ).
Discussion
In the light of previous studies showing that NO-donors are chemosensitizers 5, 16, 17 , several NObased strategies, such as the use of the ABC transporters inhibitors conjugated with NO 28 Interestingly the cytotoxicity elicited by NitDOX or FurDOX was higher than the cytotoxicity elicited by the same amount of DOX co-incubated with the corresponding NO-releasing molecule (i.e. the methyl ester of acid containing nitrooxy moiety NitE and the methyl ester of acid containing phenylsulfonylfuroxan moiety FurE, respectively). This result suggested that the cytotoxicity of NitDOX and FurDOX was not simply the sum of increased NO release and increased retention of DOX, but resulted from different pharmacodynamic effects.
FurDOX, the most effective NO-releasing DOX against drug-resistant cells, was also highly cytotoxic for cardiomyocytes in vitro, while conversely NitDOX was not more toxic than DOX.
The protective or toxic effects of NO on cardiomyocytes are difficult to predict, because NO may act either as ROS scavenger or generator (favoring the synthesis of peroxynitrite), depending on the relative stoichiometry between NO and ROS 8 . This complexity may explain the discrepant reports on the effects of NO in cardiomyocytes 32 , 33,34 and the different behaviour of NitDOX and FurDOX in H9c2 cells. Although we cannot infer any conclusion about the in vivo cardiotoxicity from these in vitro assays, it is noteworthy that NitDOX was a more potent cytotoxic agent than DOX and was capable to overcome drug resistance 18 . In the light of these premises, it might be administered at lower doses than DOX. Since cardiotoxicity of DOX is dose-dependent, this feature of NitDOX might decrease the risk of cumulative cardiac damages of DOX in a putative administration in vivo.
We cannot state that NitDOX was selective against cancer cells, since it induced the same cytotoxicity of DOX in non transformed colon epithelial cells; however, being more cytotoxic than DOX against colon cancer cells 18 , NitDOX might be used in vivo at lower concentrations than DOX, exerting good efficacy against cancer cells and limited toxicity against colon epithelium.
An intriguing difference between DOX and NitDOX is that the latter was a less potent inhibitor of topoisomerase II, one of the known targets of anthracyclines. We postulate that the presence of nitrooxy group makes NitDOX less able to bind topoisomerase than DOX. On the other hand, this result led us to hypothesize that the cell toxicity of NitDOX was independent from topoisomerase II inhibition and could be due to other mechanisms, such as a more favorable kinetics of uptake and/or different cellular targets.
The rate of DOX uptake was lower in drug-resistant cells than in drug-sensitive ones and was dependent on both passive diffusion and facilitated diffusion via SLC22A4, as shown by employing the SLC22A4 inhibitor TEA. High levels of SLC22A4 confer sensitivity to DOX by increasing the amount of the drug uptake by cells 21 and indeed the transporter was slightly lower in HT29-dx cells than in HT29 cells. NitDOX uptake was equal in drug-sensitive and drug-resistant cells, TEAinsensitive, appearing independent on SLC22A4, and more rapid than the uptake of DOX. NitDOX was more hydrophobic than DOX; this feature may facilitate its passive diffusion across the plasma membrane and explain its rapid uptake.
At the same time, the higher hydrophobicity limited the nuclear entry of NitDOX and favored the delivery through highly impermeant membranes, like the internal mitochondrial membrane, highlighting a second difference between DOX and NitDOX. In keeping with our observation on the mitochondrial localization of NitDOX, it has been reported that synthetic acyl-conjugated DOXs, more hydrophobic than the parental drug, are more uptaken by drug-resistant cells and display a cytosolic rather than a nuclear localization 35 .
Also the level of ABC transporters in subcellular compartments, that is highly variable and cell type-dependent 36, 37, 38 , strongly affects the intracellular distribution of anthracyclines. In our model, the rate of nitration and extrusion activity of Pgp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2 did not appear to underlie the nuclear-cytosolic partition of DOX and NitDOX. Interestingly, all these ABC transporters were detected in mitochondrial extracts of HT29 and HT29-dx cells, which had a greater amount of MRP1/ABCC1. Considering the nitration pattern of MRP1/ABCC1 and BCRP/ABCG2 and the reversing effects of PTIO, which lowered the amount of mitochondrial NitDOX, we postulate that the mitochondrial retention of NitDOX also relies on the reduced efflux through ABC transporters, subsequent to their nitration.
The enhanced intramitochondrial accumulation of DOX was not peculiar of all NO-releasing molecules: the NO-donors co-incubated with DOX increased the content of DOX both in whole cell and in the nucleus, likely as a consequence of the nitration of ABC transporters in HT29 and HT29dx cells 5,6 , but did not change the DOX retention within mitochondria. Only NitE produced a slight but not significant increase of intramitochondrial DOX, which remained lower than the one obtained with NitDOX. This result suggests that the nitrooxy group conjugated with DOX is more potent as a nitrating agent of the mitochondrial ABC transporters than its ester derivative. In NitDOX, the nitrooxy group is part of a highly hydrophobic molecule; therefore it is particularly favored to cross the mitochondrial membranes delivered by such a carrier. Once entered, the mitochondrial aldehyde dehydrogenase responsible of the metabolism of nitrates can produce NO from nitrooxy group 39 , increasing the intramitochondrial release of NO. As evidenced by the analysis of NitDOX metabolites in mitochondrial extracts, about 25% of NitDOX was denitrated, suggesting that NO was released from the compound within mitochondria. Of note, whereas DOX was highly converted into a more reduced metabolite suggestive of doxorubicinol 27 in both nucleus and mitochondria, the amount of NitDOX metabolized was proportionally lower. This difference, which can be due to a lower affinity of NitDOX for the catabolising enzymes, may contribute to maintain relatively high the amount of mitochondrial NitDOX.
Overall, we suggest that the different intracellular distribution of NitDOX versus DOX is the sum of at least two factors: the passive diffusion of the compound into subcellular compartments, that depends on its hydrophobicity, and the lower rate of extrusion, that relies on the activity of ABC transporters in each cell compartment. The hydrophobicity of NitDOX and the release of NO followed by the nitration of ABC transporters in mitochondria, both contribute to the high mitochondrial accumulation of NitDOX.
The mitochondrial delivery of NitDOX, which occurred in both sensitive and resistant cells, points out a novel and unexpected mechanism of cytotoxicity of this compound, in line with other works that propose a possible mitotoxic effect for some anthracyclines. For instance daunorubicin increases the mitochondrial respiration at low concentrations and inhibits it at higher concentrations, thus acting as a mitotoxic drug 40 . Recently a liposomal daunorubicin targeting mitochondria has been shown to exert high cytotoxicity in MCF7-Adr cells in association with the calcium channel blocker amlodipine, by disrupting the mitochondrial potential, releasing the cytochrome c and activating the caspases cascade 41 . This finding confirms that the mitochondrial metabolism is critical for the survival of drug-resistant cells and is in keeping with what we observed in HT29-dx, where the TCA cycle, the electron transport across complex I and the synthesis of ATP were higher than in HT29 cells. The preferential delivery of NitDOX within mitochondria may explain its greater efficacy in inducing cytotoxicity.
It is well established that NO affects mitochondrial energy metabolism 14 . For instance it elicits the tyrosine nitration of TCA cycle enzymes like aconitase and isocitrate dehydrogenase, as well as enzymes important for the synthesis of ubiquinone and for the integrity of Fe-S clusters 42 , and inhibits complex I and IV 43 . These mechanisms may account for the observed effects of NitDOX to decrease the TCA cycle, the activity of complex I and the synthesis of ATP.
Proper mitochondrial respiration protects cells against oxygen toxicity 44 . Conversely high levels of NO irreversibly damage mitochondrial respiratory chain components, resulting in oxidative and nitrosative stress, lipid peroxidation, loss of cytochrome c from permeabilized mitochondria, and activation of caspases 45 . All these events were elicited by NitDOX and relied on the release of NO from the compound, because they were prevented by PTIO. Noteworthy, a significant activation of cytochrome c/caspase-9/caspase-3 axis was achieved equally in drug-sensitive and drug-resistant cells.
In conclusion, we propose nitrooxy-doxorubicin as a new multi-target lead compound, whichoriginally designed as a MDR-reversing agenthas revealed a novel and unexpected mechanism of action. The simple addition of a NO-releasing group in form of nitrooxy made NitDOX a functionally distinct anthracycline, with a more favorable toxicity profile and a better efficacy against drug-resistant cells. In the context of earlier attempts to use NO-delivery strategies in cancer therapy 46, 47 , we believe that NitDOX is worthy of further investigations in preclinical and clinical settings. 
